ANTI-RH(D) FOR THE TREATMENT OF HEPATITIS C ASSOCIATED IMMUNE THROMBOCYTOPENIA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定是研究者机构。本研究的主要目的是评估抗RH（D）治疗在丙型肝炎相关血小板减少症（血小板异常低的一种情况）中升高血小板计数的有效性和安全性。预计如果在该患者组中观察到抗Rh（D）的获益，将进行一项更大规模的前瞻性随机试验，以比较抗Rh（D）与其他常用治疗方式，如皮质类固醇或IVIg。由于目前治疗方式的问题和缺乏真正的标准治疗这些患者，前瞻性随机研究等待确定额外的有效和耐受性良好的治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this study are to assess the effectiveness and safety of Anti-RH (D) therapy in elevating platelet counts in Hepatitis C associated thrombocytopenia (a condition when platelets are abnormally low). It is anticipated that if a benefit is seen with Anti-Rh (D) in this patient group, a larger prospective randomized trial will be conducted to compare Anti-Rh (D) to other commonly used treatment modalities, such as corticosteroids or IVIg. Because of the problems with current treatment modalities and the lack of a true standard of care in these patients, prospective randomized studies await the determination of additional effective and well-tolerated therapies.